Serious infections in patients on biologics (observational studies)
| Study ID | Registry | Intervention | Control | aHR (Intervention vs comparator/control) | Risk of bias |
|---|---|---|---|---|---|
| Serious infections | |||||
| Galloway (2011) Rheumatology (a)11 | BSRBR | 3 TNFi | csDMARDs | 1.2 (1.1, 1.5) | Low |
| Greenberg (2010) ARD12 | CORRONA | 3 TNFi+MTX | MTX | 1.1 (1.0, 1.3) | Low |
| Grijalva (2011) JAMA13 | Claim database | 3 TNFi | csDMARDs | 1.1 (0.9, 1.2) | Moderate |
| Grijalva (2010) Rheumatology14 | Claim database | 3 TNFi | MTX | 1.3 (0.8, 2.2) | Moderate |
| Komano (2011) J Rheum15 | REAL | ETA/IFX | csDMARDs | RR 2.4 (1.1, 5.1) | Moderate |
| Sakai (2012) AC&R16 | REAL | ETA/IFX | csDMARDs | RR 2.0 (1.3, 3.2) | Moderate |
| Strangfeld (2011) ARD17 | RABBIT | 3 TNFi | csDMARDs | 1.8 (1.2, 2.7) | Low |
| Lane (2011) Medicine (Baltimore)18 | Claim database | 3 TNFi | csDMARDs | 1.2 (1.0, 1.5) vs HCQ, SSZ, gold | Moderate |
| Galloway (2011) Rheumatology (b)19 | BSRBR | Anakinra | csDMARDs | 1.6 (0.9, 2.7) | Low |
| Herpes zoster | |||||
| Galloway (2013) ARD20 | BSRBR | 3 TNFi | csDMARDs | 1.7 (1.1, 2.7); adjusted for drop-outs 1.5 (1.0, 2.4) | Low |
| McDonald (2009) Clin Inf Diseases21 | Claim Database | 3 TNFi | csDMARDs | 1.4 (1.1, 1.8) | Moderate |
| Strangfeld (2009) JAMA22 | RABBIT | 3 TNFi | csDMARDs | 1.6 (1.0, 2.7) | Low |
| Garcia-Doval (2010) ARD23 | BIOBADASER | TNFi (3?) | General population | 10 (3, 26) | Low |
| Winthrop (2013) JAMA24 | Claim Dabatase | 3 TNFi | csDMARDs | 1.0 (0.8, 1.3) | Moderate |
| Tuberculosis | |||||
| Dixon (2010) ARD (a)25 | BSRBR | 3 TNFi | csDMARDs | NA | Low |
| Tam (2010) Clin Exp Rheumatol26 | Hong Kong Cohort | 3 TNFi | General population csDMARDS | 34.9 (8.9, 137.2) 12.5 (3.5, 44.7) | Moderate |
| Tubach (2009) A&R27 | RATIO | 3 TNFi | General population | 12.4 (9.1, 16.9) | Low |
| Winthrop ARD28 | Claim database | 3 TNFi | General population | NA | Moderate |
More details are found in online supplementary tables S1–S20.
aHR, adjusted HR; BIOBADASER, Spanish Biologics Register; BSRBR, British Society of Rheumatology Biologics Register; CORRONA, Consortium of Rheumatology Researchers of North America; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; ETA, etanercept; HCQ, hydroxychloroquine; IFX, infliximab; MTX, methotrexate; NA, not available (not mentioned in the original article); RABBIT, Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT (in German)); RATIO, French Biologics Register; REAL, Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety; SSZ, sulfasalazine; TNFi, tumour necrosis factor α inhibitor.